Legend Biotech USA, Inc.
Legend Biotech is a global, commercial-stage biotechnology company dedicated to developing, manufacturing, and commercializing novel therapies. The company focuses on innovative technologies to deliver cutting-edge options for patients worldwide, with a mission to cure cancer and other intractable diseases. They aim to be a global leader in cell and gene therapy by creating transformative therapies that change treatment paradigms, prioritizing patient needs, fostering innovation, promoting a collaborative culture, and conducting business with integrity.
Industries
Nr. of Employees
Very Large (1000+)
Legend Biotech USA, Inc.
Piscataway, New Jersey, United States, North America
Products
BCMA-targeting CAR-T therapy (commercially approved)
A BCMA-targeted autologous CAR-T therapy that progressed through clinical development and received regulatory approval for use in relapsed or refractory multiple myeloma.
Investigational armored and targeted autologous CAR-T therapies
Investigational autologous CAR-T programs including armored CAR constructs (e.g., constructs designed to modulate TGF-β signaling) and tumor antigen-targeted products for solid tumors such as DLL3-targeted constructs.
BCMA-targeting CAR-T therapy (commercially approved)
A BCMA-targeted autologous CAR-T therapy that progressed through clinical development and received regulatory approval for use in relapsed or refractory multiple myeloma.
Investigational armored and targeted autologous CAR-T therapies
Investigational autologous CAR-T programs including armored CAR constructs (e.g., constructs designed to modulate TGF-β signaling) and tumor antigen-targeted products for solid tumors such as DLL3-targeted constructs.
Services
End-to-end cell therapy development services
Integrated services spanning discovery, antibody screening, CAR construct optimization, preclinical validation, clinical development support, manufacturing coordination, and commercialization planning.
Strategic collaborations and business development
Partnership formation for co-development of cell therapy technologies and clinical assets in oncology and immune cell engineering.
Scientific communications and conference materials support
Preparation and distribution of conference posters, presentations and sponsored publication materials to communicate preclinical and clinical results.
End-to-end cell therapy development services
Integrated services spanning discovery, antibody screening, CAR construct optimization, preclinical validation, clinical development support, manufacturing coordination, and commercialization planning.
Strategic collaborations and business development
Partnership formation for co-development of cell therapy technologies and clinical assets in oncology and immune cell engineering.
Scientific communications and conference materials support
Preparation and distribution of conference posters, presentations and sponsored publication materials to communicate preclinical and clinical results.
Expertise Areas
- Cell therapy development
- Immuno-oncology
- Antibody discovery and engineering
- Clinical trial management and execution
Key Technologies
- CAR engineering and optimization
- Autologous and allogeneic cell processing
- CAR-NK therapies
- Gamma-delta (γδ) T cell therapies